{"id":985300,"date":"2026-07-27T20:43:05","date_gmt":"2026-07-28T00:43:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/"},"modified":"2026-07-27T20:43:05","modified_gmt":"2026-07-28T00:43:05","slug":"zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/","title":{"rendered":"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law"},"content":{"rendered":"

<\/p>\n

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law<\/b><\/p>\n

LOS ANGELES–(BUSINESS WIRE<\/a>)–Schall, Brown & Schwartz<\/a> LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (\u201cZevra\u201d or \u201cthe Company\u201d) (NASDAQ: ZVRA<\/a>) for violations of the securities laws.<\/p>\n

INVESTIGATION DETAILS: <\/b>The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. On July 24, 2026, Zevra received a negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) on the Marketing Authorization Application for arimoclomol, branded Meplyffa. Based on this news, shares of Zevra fell sharply on the same day.<\/p>\n

If you are a shareholder who suffered a loss, click here to participate<\/a>.<\/p>\n

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com<\/a>, or by email at david@schallfirm.com<\/a><\/p>\n

WHY SBS?<\/b> Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.<\/p>\n

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260727201341\/en\/<\/a><\/span><\/p>\n

Schall, Brown & Schwartz LLP
Brian Schall, Esq.
Andrew Brown, Esq.
David Schwartz, Esq.
www.schallfirm.com<\/a>
Office: 310-301-3335
info@schallfirm.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (\u201cZevra\u201d or \u201cthe Company\u201d) (NASDAQ: ZVRA) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. On July 24, 2026, Zevra received a negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) on the Marketing Authorization Application for arimoclomol, branded Meplyffa. Based on this news, shares of Zevra fell sharply on the same day. … <\/p>\n

Continue reading “ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-985300","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (\u201cZevra\u201d or \u201cthe Company\u201d) (NASDAQ: ZVRA) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. On July 24, 2026, Zevra received a negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) on the Marketing Authorization Application for arimoclomol, branded Meplyffa. Based on this news, shares of Zevra fell sharply on the same day. … Continue reading "ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T00:43:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260727201341r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law\",\"datePublished\":\"2026-07-28T00:43:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/\"},\"wordCount\":323,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260727201341r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/\",\"name\":\"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260727201341r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-07-28T00:43:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260727201341r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260727201341r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/","og_locale":"en_US","og_type":"article","og_title":"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk","og_description":"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (\u201cZevra\u201d or \u201cthe Company\u201d) (NASDAQ: ZVRA) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. On July 24, 2026, Zevra received a negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) on the Marketing Authorization Application for arimoclomol, branded Meplyffa. Based on this news, shares of Zevra fell sharply on the same day. … Continue reading \"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-28T00:43:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260727201341r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law","datePublished":"2026-07-28T00:43:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/"},"wordCount":323,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260727201341r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/","name":"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260727201341r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-07-28T00:43:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260727201341r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260727201341r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zvra-investors-have-opportunity-to-join-zevra-therapeutics-inc-fraud-investigation-with-sbs-law\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=985300"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985300\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=985300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=985300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=985300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}